Purification Process Enhancement: From 51% Yield To 87% With Targeted Impurity Removal

As drug candidates progress into mid‑stage clinical development, inefficient purification strategies can quickly become a major constraint on supply, cost, and timelines. Repetitive crystallization steps, while sometimes effective at meeting purity requirements, often signal deeper gaps in impurity understanding and process control that limit manufacturability at scale.

In this example, a multistep API process was burdened by low crystallization yield driven by persistent impurities. Rather than further refining an inefficient approach, the purification challenge was addressed at its root. Through detailed impurity profiling and mechanistic analysis, the origins of key impurities were identified and linked back to specific stages of the synthetic process. This insight enabled the design of a targeted purification strategy that removed impurities before final crystallization.

Replacing multiple recrystallizations with a streamlined, chemically informed workflow significantly increased yield, improved cycle time, and lowered solvent usage. The optimized process met all quality requirements while supporting uninterrupted clinical manufacturing, demonstrating the value of deep process understanding in mid‑stage development.